UTHR — UNITED THERAPEUTICS CORPORATION (Healthcare >> Drug Manufacturers - Specialty & Generic)
UTHR FAQ
What is UTHR's P/E ratio?
UNITED THERAPEUTICS CORPORATION (UTHR) currently trades at a P/E ratio of 18.12.
What is UTHR's ROE?
UNITED THERAPEUTICS CORPORATION reports a Return on Equity (ROE) of 21.82%.
What is UTHR's dividend yield?
UNITED THERAPEUTICS CORPORATION offers a dividend yield of 0.00%.
What is UTHR's Deepscope Quality Score?
Deepscope rates UTHR's overall financial quality at 85 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy UTHR?
Deepscope's AI Timing Score for UTHR is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does UTHR belong to?
UNITED THERAPEUTICS CORPORATION is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 549.47
Price
9.42
(1.74%)
Day Change
|
|
|---|
UTHR มีคุณภาพโดยรวมดีมาก ( คะแนนปัจจัยพื้นฐาน = 85) แต่ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
อัตราเร่งของการเติบโตของอัตราผลตอบแทนผู้ถือหุ้น (ROE) ต่ำกว่าเกณฑ์
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ยังไม่ดีนัก สุขภาพทางการเงิน ยังไม่ดีนัก และ ประสิทธิภาพการทำกำไร ดี , ...
| ปัจจัยทางคุณภาพ |
|
57% |
| In Recommendations? | In "Invest - GOOD" Section |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
583
|
| Magic Formula Rank by ROE |
583
|
| Magic Formula Rank by ROIC |
609
|
| Price | 549.47 |
| PBV / Sector |
3.95 / 2.65
|
| Earning Per Share | 30.33 |
| PE / Sector |
18.12 / 22.64
|
| PEG or PE/Growth / Sector |
0.78 / 0.11
|
| Average 1M Daily Value |
228.83 M
GREAT
|
| Average 1W Daily Value |
245.05 M
GREAT
|
| ปัจจัยทางเทคนิค |
|
28% |
| สุขภาพทางการเงิน |
|
58% |
| ประสิทธิภาพการทำกำไร |
|
72% |
| ผลตอบแทนต่อผู้ถือหุ้น |
|
4% |
| รายละเอียดการจดทะเบียน |
| Analyze Date | 2026-06-04 09:24:06 |
| Symbol | UTHR |
| Name | UNITED THERAPEUTICS CORPORATION |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 42.45 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 23,323.20 / 9,480.84 |
| ข่าว, ประมาณการ, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1000 Spring Street, Silver Spring, MD, United States, 20910
Phone: 301 608 9292
Website: https://www.unither.com
Employees: 1,400
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google